New Zealand's Pharmac launches public consultation to expand access to four cancer medicines, including pembrolizumab and nivolumab.

New Zealand's Pharmaceutical Management Agency (Pharmac) has launched its first public consultation after receiving a budget boost, focusing on expanding access to four cancer medicines. The proposed additions include two targeted cancer treatments, pembrolizumab (Keytruda) and nivolumab (Opdivo), set to be funded from October 1 for eligible patients with various cancers. The public consultation, which will run until July 26, aims to widen access to these immunotherapies and impact patients' lives by slowing cancer progression.

July 05, 2024
6 Articles